1Y Close · As of Aug 26, 2026
HLB Genex operates in the Pharmaceuticals sector.
Legal name: HLB Genex, Inc.
In fiscal year 2025, HLB Genex (187420) reported revenue of 43.4 billion KRW, up 22.4% from 35.4 billion KRW a year earlier.
Operating profit was 1.2 billion KRW and net income was 22.9 billion KRW in the same year.
As of the Aug 26, 2026 close, the market capitalization was 60.8 billion KRW, with a P/B of 1.11.
These figures can be verified in the DART filing (receipt no. 20260320001238).
Financials
| Year | Rev | Op Inc | Net Inc |
|---|---|---|---|
| 2025 | 43.4B | 1.2B | 22.9B |
| 2024 | 35.4B | -1.9B | -17.9B |
| 2023 | 27.0B | -9.5B | -722M |
Recent Filings
Early CB Acquisition (Including Overseas CB)
Semi-Annual Report (2026.06)
Large Shareholding Report (General)
Checks
1 of 8 checked items currently applicable.
Market Cap & Price: Market cap is above the delisting threshold.
Administrative Designation: No administrative designation criteria met.
Audit Opinion: Audit opinion: Unqualified (clean).
Capital Increase: No capital-increase filings in the last 180 days.
Treasury Stock: No treasury stock filings.
Embezzlement & Litigation: No embezzlement or litigation filings in the last 180 days.
Major Shareholder Change: No major shareholder changes in the last 180 days.
Market Action: No market actions recorded in the last 180 days.
Recent Filings
| Date | Filing |
|---|---|
| 2026-08-14 | Early CB Acquisition (Including Overseas CB) |
| 2026-08-13 | Semi-Annual Report (2026.06) |
| 2026-08-06 | Large Shareholding Report (General) |
| 2026-08-06 | Officer/Major Shareholder Ownership Report |
| 2026-07-29 | Officer/Major Shareholder Ownership Report |